ARO-ANG3 will be tested also in HoFH patients enrolled in the Gateway (Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia) trial (NCT05217667). This evidence concerns the gene CYP19A1 and homozygous familial hypercholesterolemia.